In the long-term management of psychotic disorders including, Schizophrenia, Mania, Organic brain syndrome
Intramuscular Psychoses; Mania; Schizophrenia Adult: As decanoate: Initially, 12.5 mg adjusted according to response. Maintenance: 12.5-100 mg at intervals of 2-6 wk. For doses >50 mg, increments should be made slowly in steps of 12.5 mg. Elderly: 6.25 mg adjusted according to response. Hepatic impairment: Use with caution; monitor
Safety and efficacy not established
Renal impairment: Use with caution; monitor
Fluphenazine Decanoate oily Injection is contraindicated in patients with hypersensitivity to the drug. Also contraindicated in comatose or severely depressed states, blood dyscrasias, liver disease, pregnancy (3rd trimester), lactation.
Fluphenazine blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system and decreases the release of hypothalamic and hypophyseal hormones. It reduces aggressiveness with disappearance of hallucinations and delusions.
Special precaution should be practiced in presence of convulsive disorders; hepatic, renal, cerebrovascular, respiratory and cardiovascular diseases. Also precaution should be observed in case of phenochromocytoma; bone marrow suppression; elderly or debilitated patients. Lactation: Drug enters breast milk; not recommended
Frequency Not Defined Confusion,Decreased gag reflex Extrapyramidal symptoms Akathisia,Dystonia,Dyskinesia,Muscle stiffness,Neuroleptic malignant syndrome (NMS; infrequent but serious),Parkinsonism,Tardive dyskinesia Common Anticholinergic effects,Sedation,Weight gain,Erectile dysfunction,Oligomenorrhea or amenorrhea, Less common Orthostatic hypotension (after IM injection), tachycardia,Agitation, anxiety, cerebral edema, depression, dizziness, euphoria, headache, poikilothermia, restlessness, weakness,Anorexia, constipation, dyspepsia, ileus,Lens opacities (with prolonged use) Uncommon ECG changes,Photosensitivity,Pruritus,Diarrhea,Blood dyscrasia,Galactorrhea,Ejaculatory disorder Rare Seizure,Priapism,Cholestatic jaundice
Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics. Potentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.